ImmunityBio (IBRX) Short Interest Ratio & Short Volume $2.74 -0.11 (-3.86%) Closing price 04:00 PM EasternExtended Trading$2.74 +0.00 (+0.04%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ImmunityBio Short Interest DataImmunityBio (IBRX) has a short interest of 60.93 million shares, representing 52.67% of the float (the number of shares available for trading by the public). This marks a 6.97% increase in short interest from the previous month. The short interest ratio (days to cover) is 9.4, indicating that it would take 9.4 days of the average trading volume of 5.48 million shares to cover all short positions.Current Short Interest60,930,000 sharesPrevious Short Interest56,960,000 sharesChange Vs. Previous Month+6.97%Dollar Volume Sold Short$200.46 millionShort Interest Ratio9.4 Days to CoverLast Record DateFebruary 28, 2025Outstanding Shares853,442,000 sharesShort Percent of Float52.67%Today's Trading Volume3,908,278 sharesAverage Trading Volume5,479,059 sharesToday's Volume Vs. Average71% Short Selling ImmunityBio? Sign up to receive the latest short interest report for ImmunityBio and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIBRX Short Interest Over TimeIBRX Days to Cover Over TimeIBRX Percentage of Float Shorted Over Time Remove Ads ImmunityBio Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/28/202560,930,000 shares $200.46 million +7.0%52.7%9.4 $3.29 2/15/202556,960,000 shares $206.20 million +1.9%49.2%9.5 $3.62 1/31/202555,920,000 shares $192.92 million +2.5%N/A9.5 $3.45 1/15/202554,540,000 shares $130.35 million +9.1%N/A7.3 $2.39 12/31/202450,010,000 shares $128.03 million +12.6%N/A7.6 $2.56 12/15/202444,410,000 shares $127.46 million -10.8%N/A7.3 $2.87 11/30/202449,780,000 shares $250.89 million -4.4%31.2%9.8 $5.04 11/15/202452,050,000 shares $233.70 million -1.3%32.6%10.3 $4.49 10/31/202452,750,000 shares $274.83 million +2.3%33.1%10.8 $5.21 10/15/202451,580,000 shares $190.85 million -2.1%32.3%18.4 $3.70 Get the Latest News and Ratings for IBRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ImmunityBio and its competitors with MarketBeat's FREE daily newsletter. 9/30/202452,680,000 shares $195.97 million +3.8%33.0%19.2 $3.72 9/15/202450,740,000 shares $181.65 million -1.1%31.8%17.9 $3.58 8/31/202451,290,000 shares $202.60 million +4.3%32.2%16.3 $3.95 8/15/202449,180,000 shares $195.74 million +5.2%31.6%15.2 $3.98 7/31/202446,770,000 shares $240.87 million -3.5%30.3%13.5 $5.15 7/15/202448,480,000 shares $308.33 million -1.2%31.4%7.5 $6.36 6/30/202449,080,000 shares $310.19 million -8.2%31.8%7.2 $6.32 6/15/202453,440,000 shares $318.50 million -0.1%34.6%7.5 $5.96 5/31/202453,470,000 shares $343.28 million +0.1%34.6%7.7 $6.42 5/15/202453,430,000 shares $432.78 million -3.1%38.0%7.2 $8.10 4/30/202455,140,000 shares $440.57 million +0.6%40.1%7.8 $7.99 4/15/202454,840,000 shares $287.36 million +0.1%40.1%11.7 $5.24 3/31/202454,770,000 shares $294.11 million +2.9%41.5%13.6 $5.37 3/15/202453,250,000 shares $273.17 million +3.3%40.4%13.3 $5.13 2/29/202451,550,000 shares $243.83 million +9.4%39.4%12.2 $4.73 2/15/202447,140,000 shares $225.33 million +7.3%36.1%11.4 $4.78 1/31/202443,930,000 shares $147.60 million +4.8%33.6%10.5 $3.36 1/15/202441,930,000 shares $161.43 million +3.5%32.1%6.8 $3.85 12/31/202340,520,000 shares $203.41 million +7.1%31.0%6.8 $5.02 12/15/202337,840,000 shares $162.71 million +4.7%N/A6.5 $4.30 11/30/202336,140,000 shares $133.00 million +1.4%N/A6.6 $3.68 11/15/202335,660,000 shares $145.85 million -14.9%N/A6.7 $4.09 10/31/202341,920,000 shares $131.63 million +0.7%N/A8.7 $3.14 10/15/202341,640,000 shares $54.55 million +5.3%N/A13.7 $1.31 9/30/202339,540,000 shares $66.82 million +8.5%30.2%14.6 $1.69 9/15/202336,440,000 shares $65.59 million +36.4%19.8%14.1 $1.80 8/31/202326,720,000 shares $43.02 million +17.4%23.5%10.7 $1.61 8/15/202322,760,000 shares $44.61 million -4.8%20.0%8.8 $1.96 7/31/202323,900,000 shares $52.58 million -0.8%22.0%6.1 $2.20 7/15/202324,100,000 shares $67.00 million +3.5%22.2%5.3 $2.78DOGE Social Security bombshell? (Ad)Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.>>Here are the NINE stocks everyone will wish they own once Elon moves.<< 6/30/202323,290,000 shares $64.75 million -0.6%21.5%4.8 $2.78 6/15/202323,440,000 shares $65.40 million +4.7%21.6%4.6 $2.79 5/31/202322,390,000 shares $61.57 million -10.3%20.7%3.8 $2.75 5/15/202324,960,000 shares $80.37 million -16.7%23.0%4.2 $3.22 4/30/202329,980,000 shares $83.94 million +12.6%27.6%6 $2.80 4/15/202326,630,000 shares $51.40 million -0.4%24.6%6.7 $1.93 3/31/202326,730,000 shares $48.65 million +4.7%30.7%7.7 $1.82 3/15/202325,520,000 shares $36.49 million +11.7%29.3%8.1 $1.43 2/28/202322,850,000 shares $55.75 million -3.8%26.2%10.1 $2.44 2/15/202323,760,000 shares $83.16 million -1.1%29.0%12.3 $3.50 1/31/202324,030,000 shares $91.31 million +6.2%29.3%14 $3.80 1/15/202322,630,000 shares $108.17 million +0.9%27.6%14.1 $4.78 12/30/202222,430,000 shares $113.72 million -5.5%30.1%14.5 $5.07 12/15/202223,730,000 shares $159.23 million -0.4%31.8%15.8 $6.71 11/30/202223,830,000 shares $131.30 million -1.0%28.8%13.3 $5.51 11/15/202224,080,000 shares $145.68 million +1.5%29.1%14 $6.05 10/31/202223,730,000 shares $130.52 million +1.0%28.6%14.6 $5.50 10/15/202223,490,000 shares $116.04 million -5.0%28.4%14.6 $4.94 9/30/202224,720,000 shares $122.86 million +13.6%29.8%15.6 $4.97 9/15/202221,770,000 shares $139.98 million +7.8%26.3%13.5 $6.43 8/31/202220,190,000 shares $80.76 million +6.5%24.9%13.6 $4.00 8/15/202218,950,000 shares $89.63 million +1.5%23.4%11.1 $4.73 7/31/202218,680,000 shares $72.67 million +1.2%23.2%9.7 $3.89 7/15/202218,460,000 shares $83.07 million -0.4%22.9%9.2 $4.50 6/30/202218,530,000 shares $68.93 million -3.8%23.0%9 $3.72 6/15/202219,270,000 shares $61.86 million +4.3%23.9%9.6 $3.21 5/31/202218,470,000 shares $69.45 million +8.8%23.0%10.9 $3.76 5/15/202216,980,000 shares $59.26 million -1.5%21.1%11 $3.49 4/30/202217,230,000 shares $62.54 million +4.4%21.4%11.7 $3.63 4/15/202216,500,000 shares $83.33 million +3.6%20.5%11.2 $5.05 3/31/202215,930,000 shares $89.37 million -4.4%N/A10.7 $5.61 3/15/202216,670,000 shares $89.52 million +2.0%20.7%9.9 $5.37 2/28/202216,350,000 shares $111.83 million +12.2%20.3%9.6 $6.84 2/15/202214,570,000 shares $102.43 million +12.2%18.1%7.8 $7.03 1/31/202212,990,000 shares $75.60 million +4.6%16.2%7.6 $5.82 1/15/202212,420,000 shares $82.84 million +0.9%N/A7.7 $6.67 12/31/202112,310,000 shares $74.84 million +18.0%15.3%8.3 $6.08 12/15/202110,430,000 shares $59.45 million +9.4%13.0%8.3 $5.70 11/30/20219,530,000 shares $74.24 million +4.7%12.7%8.4 $7.79 11/15/20219,100,000 shares $64.97 million +2.6%12.1%9.4 $7.14 10/29/20218,870,000 shares $69.45 million -3.7%12.0%9.7 $7.83 10/15/20219,210,000 shares $85.65 million -5.3%12.4%10.5 $9.30 9/30/20219,730,000 shares $94.77 million +3.3%13.1%11.4 $9.74 9/15/20219,420,000 shares $90.15 million +2.2%12.7%10 $9.57 8/31/20219,220,000 shares $104.92 million -4.2%13.5%8.6 $11.38 8/13/20219,620,000 shares $108.23 million No Change14.2%8.9 $11.25 IBRX Short Interest - Frequently Asked Questions What is ImmunityBio's current short interest? Short interest is the volume of ImmunityBio shares that have been sold short but have not yet been closed out or covered. As of February 28th, traders have sold 60,930,000 shares of IBRX short. 52.67% of ImmunityBio's shares are currently sold short. Learn More on ImmunityBio's current short interest. What is a good short interest ratio for ImmunityBio? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IBRX shares currently have a short interest ratio of 9.0. Learn More on ImmunityBio's short interest ratio. Which institutional investors are shorting ImmunityBio? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ImmunityBio: Wolverine Trading LLC, Sculptor Capital LP, LMR Partners LLP, Group One Trading LLC, Citadel Advisors LLC, Bank of America Corp DE, Jane Street Group LLC, Susquehanna International Group LLP, Concourse Financial Group Securities Inc., Affinity Asset Advisors LLC, Bank of Montreal Can, National Bank of Canada FI, and Mirae Asset Securities USA Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for ImmunityBio? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 52.67% of ImmunityBio's floating shares are currently sold short. Is ImmunityBio's short interest increasing or decreasing? ImmunityBio saw a increase in short interest in February. As of February 28th, there was short interest totaling 60,930,000 shares, an increase of 7.0% from the previous total of 56,960,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does ImmunityBio's short interest compare to its competitors? 52.67% of ImmunityBio's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ImmunityBio: Sarepta Therapeutics, Inc. (5.74%), Vaxcyte, Inc. (10.21%), Qiagen (1.23%), Roivant Sciences Ltd. (10.42%), Revolution Medicines, Inc. (10.24%), Legend Biotech Co. (7.17%), Lantheus Holdings, Inc. (9.53%), TG Therapeutics, Inc. (18.36%), BridgeBio Pharma, Inc. (14.85%), Axsome Therapeutics, Inc. (15.09%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($23.74 billion), iShares 20+ Year Treasury Bond ETF ($10.75 billion), MicroStrategy Incorporated ($6.56 billion), Apollo Global Management, Inc. ($5.40 billion), Charter Communications, Inc. ($4.57 billion), AppLovin Co. ($4.45 billion), Capital One Financial Co. ($4.33 billion), Super Micro Computer, Inc. ($4.23 billion), Schlumberger Limited ($3.22 billion), and Royal Caribbean Cruises Ltd. ($3.06 billion). View all of the most shorted stocks. What does it mean to sell short ImmunityBio stock? Short selling IBRX is an investing strategy that aims to generate trading profit from ImmunityBio as its price is falling. IBRX shares are trading down $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ImmunityBio? A short squeeze for ImmunityBio occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IBRX, which in turn drives the price of the stock up even further. How often is ImmunityBio's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IBRX, twice per month. The most recent reporting period available is February, 28 2025. More Short Interest Resources from MarketBeat Related Companies Sarepta Therapeutics Short Interest Vaxcyte Short Interest Qiagen Short Interest Roivant Sciences Short Interest Revolution Medicines Short Interest Legend Biotech Short Interest Lantheus Short Interest TG Therapeutics Short Interest BridgeBio Pharma Short Interest Axsome Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IBRX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
